13FGuru
Sign in with Google Sign in with Discord

NASDAQ · Health Care

BIOGEN INC BIIB

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE.

Sources StockAnalysis company profile stockanalysis.com
Biotechnology: Biological Products (No Diagnostic Substances)

Company profile

Business mix

  • The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis.
  • It offers LEQEMBI for the treatment of Alzheimer’s disease; ZURZUVAE for the treatment of postpartum depression.
  • The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Current key questions

  • Can the company's products, services, or pipeline expand adoption within drug manufacturers - general?
  • How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
  • Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
Holders 2 Current sample portfolio
Public mentions 0 Videos / interviews / letters
Valuation snapshot
PE 21.01 FCF 8.4% Buyback -1.01%
2026-06-07

Current firm holders

Firm Weight Value Filing period
Gotham Asset Management Joel Greenblatt 0.2% $54.7M 2026-03-31
Glenview Capital Management Larry Robbins 0.3% $10.5M 2026-03-31

Recent trading changes over the last 4 quarters

Last 1 quarters Last 2 quarters Last 3 quarters Last 4 quarters
Net buyers 2 Last 4 13F filing periods
Net reducers 0 Last 4 13F filing periods
Unchanged holders 0 Share count unchanged
Increase amount $47.0M Estimated from net added shares
Reduction amount $0 Estimated from net reduced shares
Net share change / base shares +258.2% +256,228 / 99,228
Gotham Asset Management Joel Greenblatt 4 filing periods
13F 2025-06-30 Filed 2025-08-14
Major increase Shares 64.8% 13F value change +$7.0M
13F 2025-09-30 Filed 2025-11-14
Major increase Shares 65.5% 13F value change +$17.4M
13F 2025-12-31 Filed 2026-02-17
Minor increase Shares 2.3% 13F value change +$10.8M
13F 2026-03-31 Filed 2026-05-15
Minor increase Shares 7.8% 13F value change +$6.0M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 99,228 Last 4 periods +199,209 (+200.8%) Total shares 298,437 Value $54.7M
Glenview Capital Management Larry Robbins 2 filing periods
13F 2025-12-31 Filed 2026-02-17
New Shares - 13F value change +$51.1M
13F 2026-03-31 Filed 2026-05-15
Major reduction Shares -80.4% 13F value change -$40.7M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 0 Last 4 periods +57,019 (New) Total shares 57,019 Value $10.5M

Recent mentions

No public mentions.